← Issue №17/ week of Oct 25, 2026/Hepatology

Non-invasive fibrosis tests in Wilson Disease: Insights from the international Wilson Disease Registry and Barcelona Cohort.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=123 · Oct 20, 2026 · Clin Transl Gastro · IF 3.4

Non-invasive fibrosis tests in Wilson Disease: Insights from the international Wilson Disease Registry and Barcelona Cohort.

New evidencebiomarkerepidemiologypediatric
Clinical takeawayTransient elastography is the most accurate non-invasive test here for advanced fibrosis in Wilson disease; the 8.35 kPa cut-off was optimized in 64 patients and needs validation.
What it foundTransient elastography (TE) had the best accuracy for detecting advanced fibrosis (≥F3) in Wilson Disease (AUC=0.79), with sensitivity 0.88 and specificity 0.85 at a cut-off of ≥8.35 kPa, compared to liver biopsy.
ContextThis study provides new evidence supporting the use of TE in Wilson Disease, a condition where non-invasive fibrosis assessment has been understudied. It confirms TE's utility in this specific population, which included both adult and pediatric patients.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), "A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases," 2023 (Hepatology 77(4):1428-1455)

… Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm the diagnosis with the Leipzig score integrating Kayser-Fleischer rings, ceruloplasmin, 24-hour urinary copper, hepatic copper, and ATP7B testing, then treat with lifelong therapy: symptomatic patients begin decoppering with a chelator, either D-penicillamine or trientine, and transition to maintenance once decoppering is achieved, while asymptomatic or presymptomatic patients may begin with a lower-dose chelator or zinc; maintenance may be a lower-dose chelator (D-penicillamine or trientine) or full-dose zinc. Fulminant Wilson (acute liver failure with Coombs-negative hemolysis, AST/ALT >2, low ALP, low uric acid) or decompensated cirrhosis warrants emergency transfer for liver transplant evaluation. Screen all first-degree relatives.

American Association for the Study of Liver Diseases (AASLD), "A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases," 2023 (Hepatology 77(4):1428-1455) · reviewed 2026-07-23 ↗
Lauridsen Kirk FT … Schilsky ML · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues